Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer
Author:
Affiliation:
1. Department of Thoracic OncologyNational Cancer Center Hospital Tokyo Japan
2. Department of Pathology and Clinical LaboratoriesNational Cancer Center Hospital Tokyo Japan
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13004
Reference33 articles.
1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2. Pleural effusion as a significant prognostic factor in non‐small cell lung cancer;Naito T;Anticancer Res,1997
3. Prognostic value of pleural effusion in patients with non‐small cell lung cancer;Sugiura S;Clin Cancer Res,1997
4. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer
5. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Development and validation of the CAIL prognostic score in non‐small cell lung cancer patients with malignant pleural effusion;The Clinical Respiratory Journal;2023-09-18
2. Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy;Seminars in Respiratory and Critical Care Medicine;2023-06-12
3. The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study;Cancers;2022-12-14
4. A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis;Signal Transduction and Targeted Therapy;2022-11-19
5. Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta‐analysis;Clinical and Translational Science;2022-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3